~13 spots leftby Jun 2026

CBD for Neuropathic Pain in Spinal Cord Injury

Recruiting in Palo Alto (17 mi)
EW
Overseen byEva Widerstrom-Noga, PhD, DDS
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Recruiting
Sponsor: University of Miami
No Placebo Group
Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

The main purposes of this study are to (1) measure the effect of CBD/CBD-A on pain symptoms, pain intensity, pain unpleasantness, and skin sensitivity to hot and cold temperatures; and (2) measure the effect of CBD on brain electrical activity with electroencephalography (EEG).

Research Team

EW

Eva Widerstrom-Noga, PhD, DDS

Principal Investigator

University of Miami

Eligibility Criteria

This trial is for adults aged 18-64 with spinal cord injury who have been experiencing moderate to severe neuropathic pain for at least three months. Participants must not have significant medical illnesses, severe mental health disorders, current substance abuse issues, or be pregnant or breastfeeding without effective birth control.

Inclusion Criteria

My pain level is at least a 4 out of 10.
My neuropathic pain has been evaluated with specific questionnaires.
I have had nerve pain for at least three months.
See 1 more

Exclusion Criteria

I do not have a severe mental health condition like major depression, bipolar, schizophrenia, or PTSD.
I have a serious health condition like diabetes, heart disease, or liver problems.
You are currently misusing drugs or alcohol.
See 1 more

Treatment Details

Interventions

  • CBD (Cannabinoid)
Trial OverviewThe study tests the effects of Cannabidiol (CBD) on neuropathic pain severity and brain activity in people with spinal cord injuries. It compares CBD's impact on pain symptoms and EEG readings against a placebo.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Placebo followed by CBD/CBD-A groupExperimental Treatment2 Interventions
Participants in this group will receive a placebo on visit 2, followed by a one time of CBD/CBD-A on visit 3 after a two-week period.
Group II: CBD/CBD-A followed by placebo groupExperimental Treatment2 Interventions
Participants in this group will receive a one time dose of CBD/CBD-A on visit 2, followed by a placebo on visit 3 after a two-week period.

CBD is already approved in Canada for the following indications:

🇨🇦
Approved in Canada as Epidiolex for:
  • Seizures associated with Lennox-Gastaut syndrome
  • Seizures associated with Dravet syndrome

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
Lynn Rehabilitation CenterMiami, FL
Loading ...

Who Is Running the Clinical Trial?

University of Miami

Lead Sponsor

Trials
976
Patients Recruited
423,000+

Consortium for Medical Marijuana Clinical Outcomes Research

Collaborator

Trials
5
Patients Recruited
100+